WO2014052305A3 - Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins - Google Patents

Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins Download PDF

Info

Publication number
WO2014052305A3
WO2014052305A3 PCT/US2013/061381 US2013061381W WO2014052305A3 WO 2014052305 A3 WO2014052305 A3 WO 2014052305A3 US 2013061381 W US2013061381 W US 2013061381W WO 2014052305 A3 WO2014052305 A3 WO 2014052305A3
Authority
WO
WIPO (PCT)
Prior art keywords
mitochondrial
pgc
metformin
interfere
over
Prior art date
Application number
PCT/US2013/061381
Other languages
French (fr)
Other versions
WO2014052305A2 (en
Inventor
Michael P. Lisanti
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of WO2014052305A2 publication Critical patent/WO2014052305A2/en
Publication of WO2014052305A3 publication Critical patent/WO2014052305A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The original abstract exceeded 150 words in length. As a result, the abstract has been established as follows: Disclosed are methods for treating a tumor, specifically breast tumors. Increased mitochondrial "power" in epithelial cancer cells oncogenically promotes tumor growth, by conferring autophagy-resistance. As such, PGC-1 alph, PGC-1 beta, mitoNEET, and POLRMT should all be considered as tumor promoters or "metabolic oncogenes". Our results are consistent with numerous previous clinical studies showing that metformin (a weak mitochondrial "poison") prevents the onset of nearly all types of human cancers in diabetic patients. Metformin (a Complex I inhibitor), and other mitochondrial inhibitors, are disclosed as novel anti-cancer therapies, targeting mitochondrial metabolism in cancer cells.
PCT/US2013/061381 2012-09-26 2013-09-24 Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins WO2014052305A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261705693P 2012-09-26 2012-09-26
US61/705,693 2012-09-26
US201261709706P 2012-10-04 2012-10-04
US61/709,706 2012-10-04

Publications (2)

Publication Number Publication Date
WO2014052305A2 WO2014052305A2 (en) 2014-04-03
WO2014052305A3 true WO2014052305A3 (en) 2014-10-16

Family

ID=50389118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/061381 WO2014052305A2 (en) 2012-09-26 2013-09-24 Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins

Country Status (1)

Country Link
WO (1) WO2014052305A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131877B1 (en) 2014-04-17 2023-07-19 Immunomet Therapeutics Inc. Biguanide compounds
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CN113456819B (en) * 2021-07-23 2023-06-02 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Application of OXPHOS inhibitor as antitumor drug Alisertib synergist
CN113567407B (en) * 2021-07-26 2024-02-27 中国医学科学院血液病医院(中国医学科学院血液学研究所) Method for detecting mitochondrial function of hematopoietic cells
CN113930397B (en) * 2021-11-05 2024-02-20 曲阜师范大学 Construction and culture method for yeast cell mitochondria transplanted breast tumor cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132078A1 (en) * 2002-12-06 2004-07-08 Colca Jerry R. Antisense modulation of mitoNEET expression
WO2012075679A1 (en) * 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132078A1 (en) * 2002-12-06 2004-07-08 Colca Jerry R. Antisense modulation of mitoNEET expression
WO2012075679A1 (en) * 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KLIMCAKOVA ET AL.: "PGC-1.alpha. promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply.", CANCER RES, vol. 72, no. 6, 15 March 2012 (2012-03-15), pages 1538 - 46 *
KRAVCHENKO ET AL.: "Transcription of mammalian mRNAs by a novel nuclear RNA polymerase of mitochondrial origin.", NATURE, vol. 436, no. 7051, 4 August 2005 (2005-08-04), pages 735 - 739 *
SALEM ET AL.: "Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance.", CELL CYCLE, vol. 11, no. 22, 15 November 2012 (2012-11-15), pages 4174 - 80 *

Also Published As

Publication number Publication date
WO2014052305A2 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
MX2015014486A (en) Markers of tumor cell response to anti-cancer therapy.
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
MX2020003719A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer.
AU2018256508A1 (en) Individualized vaccines for cancer
MX2019006379A (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy.
WO2014153056A3 (en) Cancer treatment using antibodies that bing cell surface grp78
WO2012009406A3 (en) Gold particles and methods of making and using the same in cancer treatment
MX2015017485A (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases.
EA201290846A1 (en) RADIOT THERAPY COMBINED WITH HYPOXIC CELL SENSITIZERS
WO2014052305A3 (en) Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MY166014A (en) Combination therapy methods for treating proliferative diseases
AU2012229123A8 (en) Methods of treating breast cancer with anthracycline therapy
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
WO2015035250A3 (en) Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
AR096184A1 (en) ANTIBODY COMBINATION THERAPY FOR CD20 AFUCOSILATED WITH AN ANTIBODY CONJUGATE FOR CD22-DRUG
AU2018271862A1 (en) Combination therapy
WO2014145817A3 (en) Novel therapeutic target for the treatment of cancers and related therapies and methods
BR112014016723A2 (en) method for treating breast cancer
WO2014062587A3 (en) Injectable cancer compositions
NZ701974A (en) Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
MX2018006776A (en) Uses of pyrimido-pyrimidazinones to treat cancer.
TW200951438A (en) Methods for identifying nuclear receptor/ligand combinations for targeting brain tumor stem cells and for their use
GB2534478A (en) Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13840480

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13840480

Country of ref document: EP

Kind code of ref document: A2